Personal tools

MCL coexpression mm9:1322: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0001016!9.33e-32!75;UBERON:0001017!1.18e-31!73;UBERON:0004121!9.34e-29!95;UBERON:0000924!9.34e-29!95;UBERON:0006601!9.34e-29!95;UBERON:0002346!2.57e-26!64;UBERON:0003075!2.57e-26!64;UBERON:0007284!2.57e-26!64;UBERON:0000073!1.73e-24!54;UBERON:0001049!4.36e-23!52;UBERON:0005068!4.36e-23!52;UBERON:0006241!4.36e-23!52;UBERON:0007135!4.36e-23!52;UBERON:0010371!1.29e-22!73;UBERON:0010314!1.19e-19!92;UBERON:0000955!4.40e-19!47;UBERON:0006238!4.40e-19!47;UBERON:0002616!8.29e-19!46;UBERON:0003056!2.23e-18!49;UBERON:0002020!1.24e-17!34;UBERON:0003080!1.01e-16!40;UBERON:0002780!4.39e-16!39;UBERON:0001890!4.39e-16!39;UBERON:0006240!4.39e-16!39;UBERON:0003528!3.22e-14!29;UBERON:0002791!3.22e-14!29;UBERON:0001893!3.22e-14!29;UBERON:0000956!2.03e-09!21;UBERON:0001869!2.03e-09!21;UBERON:0000203!2.03e-09!21;UBERON:0000468!2.78e-08!333;UBERON:0002619!2.01e-07!17;UBERON:0000922!4.45e-07!320;UBERON:0003076!4.87e-07!12;UBERON:0003057!4.87e-07!12
|ontology_enrichment_uberon=UBERON:0001016!9.33e-32!75;UBERON:0001017!1.18e-31!73;UBERON:0004121!9.34e-29!95;UBERON:0000924!9.34e-29!95;UBERON:0006601!9.34e-29!95;UBERON:0002346!2.57e-26!64;UBERON:0003075!2.57e-26!64;UBERON:0007284!2.57e-26!64;UBERON:0000073!1.73e-24!54;UBERON:0001049!4.36e-23!52;UBERON:0005068!4.36e-23!52;UBERON:0006241!4.36e-23!52;UBERON:0007135!4.36e-23!52;UBERON:0010371!1.29e-22!73;UBERON:0010314!1.19e-19!92;UBERON:0000955!4.40e-19!47;UBERON:0006238!4.40e-19!47;UBERON:0002616!8.29e-19!46;UBERON:0003056!2.23e-18!49;UBERON:0002020!1.24e-17!34;UBERON:0003080!1.01e-16!40;UBERON:0002780!4.39e-16!39;UBERON:0001890!4.39e-16!39;UBERON:0006240!4.39e-16!39;UBERON:0003528!3.22e-14!29;UBERON:0002791!3.22e-14!29;UBERON:0001893!3.22e-14!29;UBERON:0000956!2.03e-09!21;UBERON:0001869!2.03e-09!21;UBERON:0000203!2.03e-09!21;UBERON:0000468!2.78e-08!333;UBERON:0002619!2.01e-07!17;UBERON:0000922!4.45e-07!320;UBERON:0003076!4.87e-07!12;UBERON:0003057!4.87e-07!12
|tfbs_overrepresentation_for_novel_motifs=2.1342,0.217198,0.464605,0.535892,0.346849,1.35778,1.55624,0.247459,0.257202,8.26573,0.599767,0.632897,0.247704,0.6581,0.364314,0,0.856992,0.338549,0.232269,1.3999,0.426133,1.17476,0.657163,0.345236,1.19059,0.686615,0.63639,0.572827,1.02135,0.181062,0.558142,0.960397,0.336199,0.204204,0.956447,0.0363535,3.28478,0.629145,0.820134,3.85348,0.342638,0.56353,0.0995018,0.366415,1.45501,0.524258,0.77511,0.589246,0.0835644,0.397446,0.839084,0.714419,0.995874,1.10437,1.12205,0.66551,0.406788,1.50238,0.21472,1.59383,2.16366,0.724164,0.269393,0.827522,0.677043,0.869046,1.2599,1.61148,0.935192,1.46355,2.94103,0.253541,8.23368,1.156,5.09737,1.08629,0.204132,0.763395,0.922432,0.430551,0.254777,3.35681,0.722675,0.240896,2.36544,5.55221,0.0610418,0.181203,0.780154,1.77427,1.33021,1.04409,0.973447,0.35304,2.2472,0.281222,0.244935,0.976308,0.775372,0.938145,1.56871,0.960112,1.08669,0.839694,0.838613,1.38336,0.8998,0.585058,0.435642,0.428007,0.484547,1.0885,1.93262,1.47196,1.33732,0.340765,6.93501,0.53982,0.858327,0.322606,1.16147,0.805995,0.688501,0.762461,1.39185,0.926209,0.65384,0.966541,1.25836,0.356163,1.06946,0.52828,1.2285,0.679647,1.35909,0.106956,0.500709,0.564999,1.30952,2.14327,1.74232,1.26465,0.700956,0.971067,0.831964,0.564002,0.778321,2.10357,0.503174,0.348692,1.63376,8.75335,1.10596,0.783181,0.678689,1.18867,0.71546,0.376898,0.48935,1.25034,1.31911,1.03816,0.926663,0.482185,0.82857,0.671017,0.325308,0.63125,3.3831
}}
}}

Revision as of 19:44, 26 November 2012


Phase1 CAGE Peaks

 Short description
Mm9::chr12:114252596..114252681,+p1@Pacs2
Mm9::chr4:119165168..119165223,-p1@Rimkla
Mm9::chr5:135164426..135164433,-p5@Limk1
Mm9::chr5:135164438..135164457,-p2@Limk1
Mm9::chr5:135164465..135164507,-p1@Limk1
Mm9::chr5:135164509..135164520,-p4@Limk1


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0045773positive regulation of axon extension0.0383141410538382
GO:0050772positive regulation of axonogenesis0.0383141410538382
GO:0030516regulation of axon extension0.0383141410538382
GO:0050769positive regulation of neurogenesis0.0383141410538382
GO:0048675axon extension0.0383141410538382
GO:0005925focal adhesion0.0383141410538382
GO:0050770regulation of axonogenesis0.0383141410538382
GO:0005924cell-substrate adherens junction0.0383141410538382
GO:0048468cell development0.0383141410538382
GO:0030055cell-matrix junction0.0383141410538382
GO:0050767regulation of neurogenesis0.0447704829281724
GO:0046982protein heterodimerization activity0.049626476547434
GO:0005912adherens junction0.049626476547434
GO:0051094positive regulation of developmental process0.049626476547434
GO:0016323basolateral plasma membrane0.049626476547434
GO:0048869cellular developmental process0.049626476547434
GO:0030154cell differentiation0.049626476547434



Relative expression of the co-expression cluster over median <br>Analyst:





Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>


Uber Anatomy
Ontology termp-valuen
nervous system9.33e-3275
central nervous system1.18e-3173
ectoderm-derived structure9.34e-2995
ectoderm9.34e-2995
presumptive ectoderm9.34e-2995
neurectoderm2.57e-2664
neural plate2.57e-2664
presumptive neural plate2.57e-2664
regional part of nervous system1.73e-2454
neural tube4.36e-2352
neural rod4.36e-2352
future spinal cord4.36e-2352
neural keel4.36e-2352
ecto-epithelium1.29e-2273
structure with developmental contribution from neural crest1.19e-1992
brain4.40e-1947
future brain4.40e-1947
regional part of brain8.29e-1946
pre-chordal neural plate2.23e-1849
gray matter1.24e-1734
anterior neural tube1.01e-1640
regional part of forebrain4.39e-1639
forebrain4.39e-1639
future forebrain4.39e-1639
brain grey matter3.22e-1429
regional part of telencephalon3.22e-1429
telencephalon3.22e-1429
cerebral cortex2.03e-0921
cerebral hemisphere2.03e-0921
pallium2.03e-0921
multi-cellular organism2.78e-08333
regional part of cerebral cortex2.01e-0717
embryo4.45e-07320
posterior neural tube4.87e-0712
chordal neural plate4.87e-0712


TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs




JASPAR motifs


Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}